Cantor Fitzgerald Reiterates Overweight on AbbVie, Maintains $200 Price Target
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $200 to $214
Wedbush Maintains Amazon(AMZN.US) With Buy Rating, Maintains Target Price $225
Stifel Maintains Microsoft(MSFT.US) With Buy Rating, Maintains Target Price $475
Jefferies Maintains Meta Platforms(META.US) With Buy Rating, Maintains Target Price $565
Morgan Stanley Adjusts AbbVie Price Target to $211 From $196
AbbVie Analyst Ratings
DBS Maintains Alphabet-A(GOOGL.US) With Buy Rating, Maintains Target Price $220
Citi Maintains Amazon(AMZN.US) With Buy Rating, Maintains Target Price $245
Fubon Securities Adjusts Price Target on Alphabet to $207 From $200, Maintains Buy Rating
Vertex Pharmaceuticals Analyst Ratings
Barclays Maintains Microsoft(MSFT.US) With Buy Rating, Maintains Target Price $475
Buy Rating Affirmed for Amazon Amidst Strong Q2 Performance and Positive Q3 Outlook
Buy Rating Affirmed for AbbVie Amidst Strong Financials and Strategic Management
Barclays Reaffirms Their Buy Rating on AbbVie (ABBV)
BMO Capital Maintains Amazon(AMZN.US) With Buy Rating, Raises Target Price to $230
Piper Sandler Adjusts Price Target on AbbVie to $196 From $190
Macquarie Downgrades Warner Bros. Discovery on Loss of NBA Rights to Amazon
Amazon.com Analyst Ratings
A Quick Look at Today's Ratings for Alphabet-A(GOOGL.US), With a Forecast Between $205 to $212